Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells

Ryo Yamashita, Mitsuo Sato, Tomohiko Kakumu, Tetsunari Hase, Naoyuki Yogo, Eiichi Maruyama, Yoshitaka Sekido, Masashi Kondo, Yoshinori Hasegawa

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Both pro- and anti-oncogenic roles of miR-221 and miR-222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic role in invasiveness in lung cancer, albeit only one cell line (H460) was used. To further evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines, including H460, as well as one immortalized normal human bronchial epithelial cell line, HBEC4. miR-221 and miR-222 induced epithelial-to-mesenchymal transition (EMT)-like changes in a minority of HBEC4 cells but, unexpectedly, both the microRNAs rather suppressed their invasiveness. Consistent with the prior report, miR-221 and miR-222 promoted growth in H460; however, miR-221 suppressed growth in four other cell lines with no effects in one, and miR-222 suppressed growth in three cell lines but promoted growth in two. These are the first results to show tumor-suppressive effects of miR-221 and miR-222 in lung cancer cells, and we focused on clarifying the mechanisms. Cell cycle and apoptosis analyses revealed that growth suppression by miR-221 and miR-222 occurred through intra-S-phase arrest and/or apoptosis. Finally, lung cancer cell lines transfected with miR-221 or miR-222 became more sensitive to the S-phase targeting drugs, possibly due to an increased S-phase population. In conclusion, our data are the first to show tumor-suppressive effects of miR-221 and miR-222 on lung cancer, warranting testing their potential as therapeutics for the disease.

Original languageEnglish
Pages (from-to)551-564
Number of pages14
JournalCancer Medicine
Volume4
Issue number4
DOIs
Publication statusPublished - 01-04-2015

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Cell Line
Growth
S Phase
MicroRNAs
Apoptosis
Neoplasms
Epithelial-Mesenchymal Transition
Drug Delivery Systems
Cell Cycle
Epithelial Cells
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Yamashita, R., Sato, M., Kakumu, T., Hase, T., Yogo, N., Maruyama, E., ... Hasegawa, Y. (2015). Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Medicine, 4(4), 551-564. https://doi.org/10.1002/cam4.412
Yamashita, Ryo ; Sato, Mitsuo ; Kakumu, Tomohiko ; Hase, Tetsunari ; Yogo, Naoyuki ; Maruyama, Eiichi ; Sekido, Yoshitaka ; Kondo, Masashi ; Hasegawa, Yoshinori. / Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. In: Cancer Medicine. 2015 ; Vol. 4, No. 4. pp. 551-564.
@article{302387a2794c48bebc06fe20964386dd,
title = "Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells",
abstract = "Both pro- and anti-oncogenic roles of miR-221 and miR-222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic role in invasiveness in lung cancer, albeit only one cell line (H460) was used. To further evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines, including H460, as well as one immortalized normal human bronchial epithelial cell line, HBEC4. miR-221 and miR-222 induced epithelial-to-mesenchymal transition (EMT)-like changes in a minority of HBEC4 cells but, unexpectedly, both the microRNAs rather suppressed their invasiveness. Consistent with the prior report, miR-221 and miR-222 promoted growth in H460; however, miR-221 suppressed growth in four other cell lines with no effects in one, and miR-222 suppressed growth in three cell lines but promoted growth in two. These are the first results to show tumor-suppressive effects of miR-221 and miR-222 in lung cancer cells, and we focused on clarifying the mechanisms. Cell cycle and apoptosis analyses revealed that growth suppression by miR-221 and miR-222 occurred through intra-S-phase arrest and/or apoptosis. Finally, lung cancer cell lines transfected with miR-221 or miR-222 became more sensitive to the S-phase targeting drugs, possibly due to an increased S-phase population. In conclusion, our data are the first to show tumor-suppressive effects of miR-221 and miR-222 on lung cancer, warranting testing their potential as therapeutics for the disease.",
author = "Ryo Yamashita and Mitsuo Sato and Tomohiko Kakumu and Tetsunari Hase and Naoyuki Yogo and Eiichi Maruyama and Yoshitaka Sekido and Masashi Kondo and Yoshinori Hasegawa",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/cam4.412",
language = "English",
volume = "4",
pages = "551--564",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Yamashita, R, Sato, M, Kakumu, T, Hase, T, Yogo, N, Maruyama, E, Sekido, Y, Kondo, M & Hasegawa, Y 2015, 'Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells', Cancer Medicine, vol. 4, no. 4, pp. 551-564. https://doi.org/10.1002/cam4.412

Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. / Yamashita, Ryo; Sato, Mitsuo; Kakumu, Tomohiko; Hase, Tetsunari; Yogo, Naoyuki; Maruyama, Eiichi; Sekido, Yoshitaka; Kondo, Masashi; Hasegawa, Yoshinori.

In: Cancer Medicine, Vol. 4, No. 4, 01.04.2015, p. 551-564.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells

AU - Yamashita, Ryo

AU - Sato, Mitsuo

AU - Kakumu, Tomohiko

AU - Hase, Tetsunari

AU - Yogo, Naoyuki

AU - Maruyama, Eiichi

AU - Sekido, Yoshitaka

AU - Kondo, Masashi

AU - Hasegawa, Yoshinori

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Both pro- and anti-oncogenic roles of miR-221 and miR-222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic role in invasiveness in lung cancer, albeit only one cell line (H460) was used. To further evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines, including H460, as well as one immortalized normal human bronchial epithelial cell line, HBEC4. miR-221 and miR-222 induced epithelial-to-mesenchymal transition (EMT)-like changes in a minority of HBEC4 cells but, unexpectedly, both the microRNAs rather suppressed their invasiveness. Consistent with the prior report, miR-221 and miR-222 promoted growth in H460; however, miR-221 suppressed growth in four other cell lines with no effects in one, and miR-222 suppressed growth in three cell lines but promoted growth in two. These are the first results to show tumor-suppressive effects of miR-221 and miR-222 in lung cancer cells, and we focused on clarifying the mechanisms. Cell cycle and apoptosis analyses revealed that growth suppression by miR-221 and miR-222 occurred through intra-S-phase arrest and/or apoptosis. Finally, lung cancer cell lines transfected with miR-221 or miR-222 became more sensitive to the S-phase targeting drugs, possibly due to an increased S-phase population. In conclusion, our data are the first to show tumor-suppressive effects of miR-221 and miR-222 on lung cancer, warranting testing their potential as therapeutics for the disease.

AB - Both pro- and anti-oncogenic roles of miR-221 and miR-222 microRNAs are reported in several types of human cancers. A previous study suggested their oncogenic role in invasiveness in lung cancer, albeit only one cell line (H460) was used. To further evaluate involvement of miR-221 and miR-222 in lung cancer, we investigated the effects of miR-221 and miR-222 overexpression on six lung cancer cell lines, including H460, as well as one immortalized normal human bronchial epithelial cell line, HBEC4. miR-221 and miR-222 induced epithelial-to-mesenchymal transition (EMT)-like changes in a minority of HBEC4 cells but, unexpectedly, both the microRNAs rather suppressed their invasiveness. Consistent with the prior report, miR-221 and miR-222 promoted growth in H460; however, miR-221 suppressed growth in four other cell lines with no effects in one, and miR-222 suppressed growth in three cell lines but promoted growth in two. These are the first results to show tumor-suppressive effects of miR-221 and miR-222 in lung cancer cells, and we focused on clarifying the mechanisms. Cell cycle and apoptosis analyses revealed that growth suppression by miR-221 and miR-222 occurred through intra-S-phase arrest and/or apoptosis. Finally, lung cancer cell lines transfected with miR-221 or miR-222 became more sensitive to the S-phase targeting drugs, possibly due to an increased S-phase population. In conclusion, our data are the first to show tumor-suppressive effects of miR-221 and miR-222 on lung cancer, warranting testing their potential as therapeutics for the disease.

UR - http://www.scopus.com/inward/record.url?scp=84984923986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984923986&partnerID=8YFLogxK

U2 - 10.1002/cam4.412

DO - 10.1002/cam4.412

M3 - Article

VL - 4

SP - 551

EP - 564

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -

Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E et al. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Medicine. 2015 Apr 1;4(4):551-564. https://doi.org/10.1002/cam4.412